🇺🇸 PIPERACILLIN SODIUM in United States

8,870 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Off Label Use — 1,632 reports (18.4%)
  2. Drug Ineffective — 1,442 reports (16.26%)
  3. Acute Kidney Injury — 1,020 reports (11.5%)
  4. Pyrexia — 982 reports (11.07%)
  5. Diarrhoea — 730 reports (8.23%)
  6. Condition Aggravated — 670 reports (7.55%)
  7. Pneumonia — 616 reports (6.94%)
  8. Neutropenia — 612 reports (6.9%)
  9. Thrombocytopenia — 593 reports (6.69%)
  10. Febrile Neutropenia — 573 reports (6.46%)

Source database →

PIPERACILLIN SODIUM in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is PIPERACILLIN SODIUM approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for PIPERACILLIN SODIUM in United States?

Marketing authorisation holder not available in our data.